(Q39789577)

14 September 2017

title

Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax. (English)

1 reference

14 September 2017

0 references

0 references

H Garg

1

1 reference

14 September 2017

R Salcedo

series ordinal

2

1 reference

14 September 2017

G Trinchieri

series ordinal

3

1 reference

14 September 2017

R Blumenthal

series ordinal

4

1 reference

14 September 2017

publication date

9 October 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

17

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

155-163

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2009.63

14 September 2017

exact match

0 references

cites work

hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Designing a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Transcriptional targeting of tumors with a novel tumor-specific survivin promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Survivin, versatile modulation of cell division and apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Activation of cancer-specific gene expression by the survivin promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Movement of Bax from the cytosol to mitochondria during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Rapid kinetics of tBid-induced cytochrome c and Smac/DIABLO release and mitochondrial depolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Targeted gene therapy for breast cancer with truncated Bid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

The permeability transition pore triggers Bax translocation to mitochondria during neuronal apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Bax translocation to mitochondria subsequent to a rapid loss of mitochondrial membrane potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Conformation of the Bax C-terminus regulates subcellular location and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Up-Regulation of Matrix Metalloproteinase-9 in T Lymphocytes of Mammary Tumor Bearers: Role of Vascular Endothelial Growth Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Cancer-specific activation of the survivin promoter and its potential use in gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.63

Bax gene therapy for human osteosarcoma using cationic liposomes in vivo

21 January 2018

1 reference

12 December 2020

Antitumor activity of bax and p53 naked gene transfer in lung cancer: in vitro and in vivo analysis

1 reference

12 December 2020

Protein kinase Czeta abrogates the proapoptotic function of Bax through phosphorylation

1 reference

12 December 2020

Survivin in apoptosis control and cell cycle regulation in cancer

1 reference

12 December 2020

Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.

1 reference

12 December 2020

Enhancement of Bik antitumor effect by Bik mutants

1 reference

12 December 2020

Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy

1 reference

12 December 2020

A model of BAX gene delivery to human lung cancer.

1 reference

12 December 2020

Identification of a minimal c-erbB-2 promoter region that mediates preferential expression of a linked foreign gene in human breast cancer cells.

1 reference

12 December 2020

Antitumor activity of cationic liposome-mediated Bax gene transfer in osteosarcoma cells: induction of apoptosis and caspase-independent cell death.

1 reference

12 December 2020

In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene

1 reference

12 December 2020

Cancer-specific gene therapy.

1 reference

12 December 2020

Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.

1 reference

12 December 2020

Antitumor effect of IL-2, p53, and bax gene transfer in C6 glioma cells

1 reference

12 December 2020

Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.

1 reference

12 December 2020

Identifiers

DOI

10.1038/CGT.2009.63

1 reference

14 September 2017

0 references

1 reference